Hematological ratios and cytokine profiles in heterozygous beta-thalassemia

Introduction: β-Thalassemia is defined by a reduced or complete absence of β-globin chain synthesis in hemoglobin, leading to hemolytic anemia. Heterozygous β-thalassemia, also known as β-thalassemia trait (hBTh), the mildest form of this anemia, typically does not cause symptoms in carriers. Howeve...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Carolina Marques Ciceri, Laura Eduarda de Oliveira, Ana Luísa Richter, José Antonio Mainardi de Carvalho, Maylla Rodrigues Lucena, Guilherme Wataru Gomes, Maria Stella Figueiredo, Magnun Nueldo Nunes dos Santos, Vera Lúcia Nascimento Blaia-D'Avila, Rodolfo Delfini Cançado, Elvira Maria Guerra-Shinohara, Clóvis Paniz
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137925001130
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849243038119886848
author Ana Carolina Marques Ciceri
Laura Eduarda de Oliveira
Ana Luísa Richter
José Antonio Mainardi de Carvalho
Maylla Rodrigues Lucena
Guilherme Wataru Gomes
Maria Stella Figueiredo
Magnun Nueldo Nunes dos Santos
Vera Lúcia Nascimento Blaia-D'Avila
Rodolfo Delfini Cançado
Elvira Maria Guerra-Shinohara
Clóvis Paniz
author_facet Ana Carolina Marques Ciceri
Laura Eduarda de Oliveira
Ana Luísa Richter
José Antonio Mainardi de Carvalho
Maylla Rodrigues Lucena
Guilherme Wataru Gomes
Maria Stella Figueiredo
Magnun Nueldo Nunes dos Santos
Vera Lúcia Nascimento Blaia-D'Avila
Rodolfo Delfini Cançado
Elvira Maria Guerra-Shinohara
Clóvis Paniz
author_sort Ana Carolina Marques Ciceri
collection DOAJ
description Introduction: β-Thalassemia is defined by a reduced or complete absence of β-globin chain synthesis in hemoglobin, leading to hemolytic anemia. Heterozygous β-thalassemia, also known as β-thalassemia trait (hBTh), the mildest form of this anemia, typically does not cause symptoms in carriers. However, it may lead to changes in the immune system, including an increase in total leukocyte, neutrophil, and lymphocyte counts. Objective: This study aimed to evaluate various immune and inflammation markers, including neutrophil/lymphocyte, derived neutrophil/lymphocyte, lymphocyte/monocyte, platelet/lymphocyte, neutrophil/platelet ratios, systemic immune-inflammation index, systemic inflammation response index, neutrophil/natural killer cell ratio (NNKR), and inflammatory cytokines in β-thalassemia trait carriers. Method: A retrospective observational study was conducted, including 50 β-thalassemia trait individuals and 100 healthy controls. Results: Leukocyte, neutrophil and reticulocyte counts, and interleukin 6 levels were higher in carriers compared to controls. Notably, the β-thalassemia trait group had increased neutrophil/platelet, neutrophil/lymphocyte and derived neutrophil/lymphocyte ratios, and the systemic immune-inflammation and systemic inflammation response indexes were higher compared to the controls. Conclusions: β-thalassemia trait shows a more pronounced inflammatory profile as indicated by hematological ratios. These ratios, therefore are potentially cost-effective and easily applicable markers for monitoring patients with the β-thalassemia trait.
format Article
id doaj-art-b553471f6f5a4446be9ec16eee857a51
institution Kabale University
issn 2531-1379
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Hematology, Transfusion and Cell Therapy
spelling doaj-art-b553471f6f5a4446be9ec16eee857a512025-08-20T03:59:37ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-07-0147310384510.1016/j.htct.2025.103845Hematological ratios and cytokine profiles in heterozygous beta-thalassemiaAna Carolina Marques Ciceri0Laura Eduarda de Oliveira1Ana Luísa Richter2José Antonio Mainardi de Carvalho3Maylla Rodrigues Lucena4Guilherme Wataru Gomes5Maria Stella Figueiredo6Magnun Nueldo Nunes dos Santos7Vera Lúcia Nascimento Blaia-D'Avila8Rodolfo Delfini Cançado9Elvira Maria Guerra-Shinohara10Clóvis Paniz11Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Laboratório de Pesquisas em Análises Clínicas Aplicadas - LAPACA, Santa Maria, RS, BrazilUniversidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Laboratório de Pesquisas em Análises Clínicas Aplicadas - LAPACA, Santa Maria, RS, BrazilUniversidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Laboratório de Pesquisas em Análises Clínicas Aplicadas - LAPACA, Santa Maria, RS, BrazilUniversidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Laboratório de Pesquisas em Análises Clínicas Aplicadas - LAPACA, Santa Maria, RS, BrazilUniversidade Ceuma - Campus Imperatriz, Imperatriz, MA, Brazil; Universidade Federal de São Paulo, Disciplina de Hematologia e Hemoterapia, São Paulo, SP, BrazilUniversidade Federal Fluminense, Departamento de Patologia, Niterói, RJ, BrazilUniversidade Federal de São Paulo, Disciplina de Hematologia e Hemoterapia, São Paulo, SP, BrazilUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Patologia Clínica, São Paulo, SP, BrazilPontifícia Universidade Católica de São Paulo, Faculdade de Medicina e Ciências da Saúde, Divisão de Hematologia, Sorocaba, SP, BrazilFaculdade de Ciências Médicas da Santa Casa de São Paulo, Departmento de Hematologia e Oncologia, São Paulo, SP, BrazilUniversidade Federal de São Paulo, Disciplina de Hematologia e Hemoterapia, São Paulo, SP, BrazilUniversidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Laboratório de Pesquisas em Análises Clínicas Aplicadas - LAPACA, Santa Maria, RS, Brazil; Corresponding author. Clóvis Paniz; Applied Clinical Analysis Research Laboratory (LAPACA), Department of Clinical and Toxicological Analyses, Federal University of Santa Maria, Av. Roraima, no. 1000, Building 26 G, Lab 01, 97105-900, Santa Maria, Rio Grande do Sul, Brazil.Introduction: β-Thalassemia is defined by a reduced or complete absence of β-globin chain synthesis in hemoglobin, leading to hemolytic anemia. Heterozygous β-thalassemia, also known as β-thalassemia trait (hBTh), the mildest form of this anemia, typically does not cause symptoms in carriers. However, it may lead to changes in the immune system, including an increase in total leukocyte, neutrophil, and lymphocyte counts. Objective: This study aimed to evaluate various immune and inflammation markers, including neutrophil/lymphocyte, derived neutrophil/lymphocyte, lymphocyte/monocyte, platelet/lymphocyte, neutrophil/platelet ratios, systemic immune-inflammation index, systemic inflammation response index, neutrophil/natural killer cell ratio (NNKR), and inflammatory cytokines in β-thalassemia trait carriers. Method: A retrospective observational study was conducted, including 50 β-thalassemia trait individuals and 100 healthy controls. Results: Leukocyte, neutrophil and reticulocyte counts, and interleukin 6 levels were higher in carriers compared to controls. Notably, the β-thalassemia trait group had increased neutrophil/platelet, neutrophil/lymphocyte and derived neutrophil/lymphocyte ratios, and the systemic immune-inflammation and systemic inflammation response indexes were higher compared to the controls. Conclusions: β-thalassemia trait shows a more pronounced inflammatory profile as indicated by hematological ratios. These ratios, therefore are potentially cost-effective and easily applicable markers for monitoring patients with the β-thalassemia trait.http://www.sciencedirect.com/science/article/pii/S2531137925001130Β-thalassemiaHeterozygotic thalassemiaHematologic ratiosInflammationHemolytic anemia
spellingShingle Ana Carolina Marques Ciceri
Laura Eduarda de Oliveira
Ana Luísa Richter
José Antonio Mainardi de Carvalho
Maylla Rodrigues Lucena
Guilherme Wataru Gomes
Maria Stella Figueiredo
Magnun Nueldo Nunes dos Santos
Vera Lúcia Nascimento Blaia-D'Avila
Rodolfo Delfini Cançado
Elvira Maria Guerra-Shinohara
Clóvis Paniz
Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
Hematology, Transfusion and Cell Therapy
Β-thalassemia
Heterozygotic thalassemia
Hematologic ratios
Inflammation
Hemolytic anemia
title Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
title_full Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
title_fullStr Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
title_full_unstemmed Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
title_short Hematological ratios and cytokine profiles in heterozygous beta-thalassemia
title_sort hematological ratios and cytokine profiles in heterozygous beta thalassemia
topic Β-thalassemia
Heterozygotic thalassemia
Hematologic ratios
Inflammation
Hemolytic anemia
url http://www.sciencedirect.com/science/article/pii/S2531137925001130
work_keys_str_mv AT anacarolinamarquesciceri hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT lauraeduardadeoliveira hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT analuisarichter hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT joseantoniomainardidecarvalho hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT mayllarodrigueslucena hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT guilhermewatarugomes hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT mariastellafigueiredo hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT magnunnueldonunesdossantos hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT veralucianascimentoblaiadavila hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT rodolfodelfinicancado hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT elviramariaguerrashinohara hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia
AT clovispaniz hematologicalratiosandcytokineprofilesinheterozygousbetathalassemia